ISB News

Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor.

Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.

ISB researchers have shown which blood metabolites are associated with the gut microbiome, genetics, or the interplay between both. Their findings, published in the journal Nature Metabolism, have promising implications for guiding targeted therapies designed to alter the composition of the blood metabolome to improve human health.

The recently completed, ISB-led Coaching for Cognition in Alzheimer’s (COCOA) trial shows that diet and exercise can help people suffering from dementia. Senior Research Scientist Dr. Jared Roach discussed the findings in a Research Roundtable presentation.

ISB is excited to announce the arrival of our newest faculty member, Ling/Obrzut Assistant Professor Dr. Alice Kane. The Kane Lab will investigate the biological determinants of frailty in both males and females. In this Q&A, she discusses her research to date, her areas of interest, and much more.

The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.